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Visual impairment due to glaucoma currently impacts 70 million people worldwide. While disease
progression can be slowed or stopped with effective lowering of intraocular pressure, current medical
treatments are often inadequate. Fortunately, three new classes of therapeutics that target the diseased
conventional outﬂow tissue responsible for ocular hypertension are in the ﬁnal stages of human testing.
The rho kinase inhibitors have proven particularly efﬁcacious and additive to current therapies. Un-
fortunately, non-contact technology that monitors the health of outﬂow tissue and its response to
conventional outﬂow therapy is not available clinically. Using optical coherence tomographic (OCT)
imaging and novel segmentation software, we present the ﬁrst demonstration of drug effects on con-
ventional outﬂow tissues in living eyes. Topical netarsudil (formerly AR-13324), a rho kinase/ nor-
epinephrine transporter inhibitor, affected both proximal (trabecular meshwork and Schlemm’s Canal)
and distal portions (intrascleral vessels) of the mouse conventional outﬂow tract. Hence, increased
perfusion of outﬂow tissues was reliably resolved by OCT as widening of the trabecular meshwork and
signiﬁcant increases in cross-sectional area of Schlemm’s canal following netarsudil treatment. These
changes occurred in conjunction with increased outﬂow facility, increased speckle variance intensity of
outﬂow vessels, increased tracer deposition in conventional outﬂow tissues and decreased intraocular
pressure. This is the ﬁrst report using live imaging to show real-time drug effects on conventional
outﬂow tissues and speciﬁcally the mechanism of action of netarsudil in mouse eyes. Advancements here
pave the way for development of a clinic-friendly OCT platform for monitoring glaucoma therapy.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Optical coherence tomography (OCT) is a non-contact imaging
technology that provides cross-sectional information, quantitative
analysis of ocular tissues and is widely used for imaging both anterior
and posterior segments. Twenty years ago the ﬁrst OCT images of the
cornea and anterior segment were visualized (Izatt et al., 1994). Today,
anterior segment OCT imaging is a crucial tool in the clinical practiceB.V. This is an open access article u
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sible blindness worldwide. In glaucoma practices, OCT is primarily
used to monitor retinal ganglion cell axon loss, however it is also used
anteriorly for angle assessment (Narayanaswamy et al., 2010) and
evaluating the efﬁcacy of laser procedures (Lee et al., 2011; See et al.,
2007). Moreover, OCT is routinely used to appraise tissue responses
following minimally invasive glaucoma surgeries (Jung et al., 2015;
Qian et al., 2015), as well as to evaluate bleb architecture following
trabeculectomy (Mastropasqua et al., 2014).
Major advancements in OCT technology for the anterior eye
have resulted in increased reproducibility and accuracy in the as-
sessment of progressive tissue damage (Kagemann et al., 2015; Li
et al., 2007) and enhanced penetration of the OCT signal into
ocular tissues, including conventional outﬂow structures (Francis
et al., 2012; Kagemann et al., 2014a, 2010). Interest in imaging thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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recent years since reduced aqueous humor drainage through these
tissues is the root cause of ocular hypertension in glaucoma. For
example, OCT was used to monitor mechanical responses of the
TM to acute intraocular pressure (IOP) elevation in living human
eyes. Elevated IOP reduced SC cross-sectional area (Kagemann
et al., 2015, 2014b), which was enhanced in the presence tropi-
camide, a drug that disables the ciliary muscle (Kagemann et al.,
2015).
Resolution limitations due to optical penetration constraints of OCT
into human and non-human primate eyes, has prompted study of
mouse eyes as a surrogate to learn more about conventional outﬂow
behavior. Conventional outﬂow in mouse eyes is very similar to hu-
man eyes in terms of anatomy, physiology and response to a number
of conventional outﬂow drug treatments (Aihara et al., 2003; Bous-
sommier-Calleja et al., 2012; Li et al., 2014a; Millar et al., 2011; Overby
et al., 2014a, 2014b; Smith et al., 2001). Importantly, unlike many
other models, mouse eyes have a true SC, through which 70% of
aqueous humor exits (Boussommier-Calleja et al., 2012). In terms of
imaging, there are great advantages in using OCT to monitor mouse
outﬂow tissues compared to primate eyes: mouse eyes are small, have
a large SC lumen, thin sclera, and can be immobilized under an-
esthesia during imaging sessions. For example, behavior of TM/SC can
be monitored at different IOP levels (Li et al., 2014a, 2014b) and at
different disease stages (Li et al., 2014b). Similar to healthy human
volunteers (Kagemann et al., 2015), we observed that mouse SC di-
mensions are reduced in a pressure-dependent manner that is quickly
reversible (Li et al., 2014a, 2014b). The mouse eyes also respond to
topical cholinergic treatment similar to that of human eyes (Flocks and
Zweng, 1957; Li et al., 2014a; Lutjen-Drecoll, 1973), with the ciliary
muscle contracting to maintain a patent conventional outﬂow tract (Li
et al., 2014a).
Using our custom-built OCT imaging system for mouse eyes, we
set out to monitor the effects of a new class of glaucoma drug,
netarsudil (Sturdivant et al., 2016), currently in late-stage human
clinical trials. Netarsudil primarily targets cells in the conventional
outﬂow tract, efﬁciently decreasing IOP in both human (Bacharach
et al., 2015; Levy et al., 2015; Lewis et al., 2015) and non-human
primate eyes (Wang et al., 2015). In addition, netarsudil has been
shown to increase outﬂow facility in non-human primate eyes
(Wang et al., 2015) and to decrease episcleral venous pressure in
rabbit eyes (Kiel and Kopczynski, 2015). In the present study, we
found that netarsudil lowered IOP, increased outﬂow facility and
increased tracer deposition in the trabecular meshwork of mouse
eyes. More importantly, using our newly developed OCT imaging
technologies, we discovered a novel action of the drug on the
living mouse outﬂow tissues. We observed that netarsudil induced
widening of the opening to the trabecular meshwork and in-
creases the cross-sectional area of SC without pupillary
constriction.2. Materials and methods
2.1. Animals
Mice were handled in accordance with animal care and use
guidelines of Duke University and in compliance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research.
C57BL/6 (C57) and CD1 mice were purchased from the Jackson La-
boratory (Bar Harbor, Maine, USA), bred/housed in clear cages and
kept in housing rooms at 21 °C with a 12 h: 12 h light-dark cycle. Mice
were examined at ages between 2 and 5 months old.Please cite this article as: Li, G., et al., Visualization of conventional o
Pharmacol (2016), http://dx.doi.org/10.1016/j.ejphar.2016.04.002i2.2. Intraocular pressure measurement
The right eyes from age and gender-matched C57 and CD1
sedated mice (5 mice per group) were given either 10 ml 0.04%
topical netarsudil mesylate (from here on referred to as netarsudil)
or 10 ml placebo (CF324–01) eye drop once/day for ﬁve consecutive
days. IOP of both eyes was measured prior to eye drop adminis-
tration using rebound tonometry (TonoLab) between 1 and 4 pm
daily (Li et al., 2014a). Brieﬂy, mice were anesthetized with keta-
mine (60 mg/kg) and xylazine (6 mg/kg). IOP was immediately
measured just as the mice stopped moving (light sleep). Each IOP
recorded was the average of six measurements, giving a total of 36
rebounds from the same eye.
2.3. Recovery from provocative IOP elevation
The effects of netarsudil on recovery from IOP spikes in living
mice were conducted by analyzing pressure decay curves in paired
eyes. Mice were anesthetized by intraperitoneal injection of ke-
tamine (100 mg/kg) and xylazine (10 mg/kg) and maintained with
ketamine (50 mg/kg at 20–30 min intervals). One microglass
needle was back ﬁlled with the active metabolite of netarsudil
(netarsudil-M1) (100 nM) and the other with vehicle (0.001%
DMSO). The two needles were connected to two ﬂuid reservoirs
and two pressure transducers (model 142PC01G; Honeywell, Fort
Washington, PA). Before the two needles were placed into mouse
eyes, the two needle tips were guided and immersed into tear ﬁlm
using micromanipulators. After pressure transducers were zeroed,
anterior chambers of both eyes were cannulated simultaneously
and the spontaneous IOPs were recorded. Both eyes were perfused
with drug or vehicle at 15 mmHg for 30 min, allowing drug or
vehicle to reach outﬂow tissues. The pressure in both eyes was
then elevated to 40 mmHg and held for 5 min. Once the IOPs in
both eyes were stable, the stopcocks were turned to close off the
reservoir and maintain the opening between pressure transducers
and eye interiors. Pressure was continuously recorded until re-
turning back to spontaneous IOP. To characterize the decline in
pressure over time, the data were ﬁtted with Eq. (1).
α= + ( − ) (− ) ( )p p p p texp 1ss ss0
where p0 is the IOP at the start of the experiment, which was
40 mmHg in our case, and pss is the IOP when the pressure decay
reached a steady state. α is a constant that characterized the rate of
pressure decay. The regression analysis yields the values of α and
pss in Eq. (1).
2.4. Outﬂow facility measurement using iPerfusion system
A system especially designed to simultaneously measure low
outﬂow facilities in paired mouse eyes, the iPerfusion system
(Sherwood et al., 2016), was used in the present study. Each freshly
enucleated mouse eye was mounted on a stabilization platform in
a perfusion chamber using a small amount of cyanoacrylate glue
(Loctite, Westlake Ohio, USA). The perfusion chamber was ﬁlled
with pre-warmed D-glucose in phosphate-buffered saline (DBG,
5.5 mM) and temperature regulated at 35 °C. A glass microneedle,
back ﬁlled with either 100 nM netarsudil-M1 or vehicle (0.001%
DMSO), was connected to the system and the microneedle was
inserted into anterior chamber using a micromanipulator.
Both eyes were perfused at 9 mmHg for 45–60 min to allow
acclimatization and deliver the drug to the outﬂow pathway, fol-
lowed by 9 sequential pressure steps of 4.5, 6, 7.5, 9, 10.5, 12, 15, 18
and 21 mmHg. Data analysis was carried out as described pre-
viously (Sherwood et al., 2016). Brieﬂy, a non-linear ﬂow-pressure
model was used to account for the pressure dependence ofutﬂow tissue responses to netarsudil in living mouse eyes. Eur J
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a reference pressure of 8 mmHg (approximates the physiological
pressure drop across the conventional outﬂow pathway in living
mice). A two-tailed paired weighted t-test carried out on the log
transformed outﬂow facility data was used to determine whether
any observed difference in reference facility between contralateral
eyes was statistically signiﬁcant.
2.5. Microbeads infusion
Two pulled glass microneedles secured onto two micro-manip-
ulators were ﬁlled with green ﬂuorescent beads (100 nm, carboxylate-
modiﬁed FluoSpheress, Molecular Probes, 1:750 dilutions) mixed
with 100 nM netarsudil-M1 or vehicle (0.001% DMSO) in 1DBG
(Dulbecco's phosphate-buffered saline, GIBCO, pH 7.3 containing
5.5 mM D-glucose). A microneedle containing netarsudil-M1 was in-
serted into the anterior chamber of one eye and a microneedle con-
taining vehicle into the contralateral eye. The two needles were con-
nected to two 1ml syringes via tubing that were locked into a single
syringe pump. Both eyes were perfused simultaneously at a rate of
0.167 ml/min for 1 h resulting in a total of 10 ml of liquid infused into
each anterior chamber. After infusion, needles were withdrawn and
mice were maintained for 1–2 h before euthanizing. Both eyes were
collected and bisected at the equator. Lens, iris and ciliary body were
removed and anterior segments were ﬂat mounted with corneal
epithelium side facing up. The ﬂuorescence images were captured
using a 2.5 lens on a ﬂuorescence microscope (Axioplan2, Carl Zeiss
MicroImaging, Thornwood, NY) using identical settings for both eyes.
The automatic computation of the width and intensity was done by a
number of image processing operations. The original image (changed
to grayscale) was converted to an edge map by applying Canny edge
detector (Canny, 1986). The edges from same region get disconnected
due to noise. Hence, the edge map was enhanced and disjoint edges
were connected by applying a morphological dilation (Serra, 1982)
operation using a circular structuring element of size 5. Afterwards, a
morphological region ﬁlling operation recovered the bounded regions.
At this stage, the applied image processing recovered the TM/SC re-
gions along with noisy isolated regions and the central region, since
the edge detection and subsequent dilation also enhance noisy pixels
as well as the central part of the image (containing high intensity).
Hence, two attributes were computed for each segmented region:
area (number of pixels) and elongation (major axis length of the best
ﬁtted ellipse to the region). Since the desired regions (TM/SC) have
large areas and elongated structures, a high threshold on area values
and elongation values each keeps only the desired regions while re-
moving unwanted noisy segmentation as well as the central region.
After ﬁnal segmentation, the center of this circular region was located,
and the width was computed at 1/10th of each degree to be more
precise. Average of the intensity of all pixels with identical angles to
the center, represents the mean intensity at the corresponding width.
2.6. Optical coherence tomographic imaging
In vivo imaging was performed utilizing an Envisu R2200 high-
resolution spectral domain (SD)-OCT system (Bioptigen Inc., Re-
search Triangle Park, NC). This 840 nm SD-OCT system utilized a
customized 180 nm Superlum Broadlighter source providing two
micron axial resolution and a 12 mm telecentric lens bore for
anterior segment OCT imaging. For experiments, mice were an-
esthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg)
and continued with ketamine (60 mg/kg) to maintain anesthesia.
The OCT probe was aimed at the inferior lateral limbus and the
image was centered and focused at SC. A sequence of repeated OCT
B-scans (each with 1000 A-scans spanning 0.5 mm in lateralPlease cite this article as: Li, G., et al., Visualization of conventional o
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averaged to create a high signal-to-noise-ratio image from the ir-
idocorneal angle region of each animal. The images from the same
SC location captured before and an average of 45 min after 10 ml
0.04% netarsudil or placebo control (CF324–01) were compared.
For experiments in which IOP was controlled, iridectomy was
conducted on mice as previously described (Li et al., 2014a, 2014b)
2–3 weeks before OCT imaging. Iridectomies were performed to
avoid artiﬁcial enhancement of outﬂow due to anterior chamber
deepening observed with single needle perfusions (Boussommier-
Calleja et al., 2015). A pulled glass micro-needle was ﬁlled with
phosphate buffered saline (PBS) and inserted into anterior cham-
ber of mice. The micro-needles were connected to both a mano-
metric column to adjust IOP and a pressure transducer to con-
tinuously monitor IOP levels (using PowerLab software). The OCT
probe was aimed at the inferior lateral limbus and the image was
centered and focused at SC. While collecting images, mouse eyes
were subjected to a series of IOP steps (10, 15, 30 mmHg) by ad-
justing the height of the ﬂuid reservoir. At each IOP step, a se-
quence of repeated OCT B-scans (each with 1000 A-scans spanning
0.5 mm in lateral length) from spatially close positions was cap-
tured, registered, and averaged to create a high signal-to-noise-
ratio image from the iridocorneal angle region of each animal.
After IOP was returned to 10 mmHg for 5 min, the eye was treated
with a 10 ml 0.04% netarsudil or placebo control (CF324–01) eye
drop. After 30–60 min, the same area of SC was imaged and again
subjected to the sequence of pressure steps. As an example, sup-
plemental Fig. 2 contains averaged OCT images and corresponding
live videos. Here real-time speckling can be visualized in both SC
and scleral vessels in the presence or absence of netarsudil.
2.7. Assessment of OCT images
OCT B-scans of iridocorneal angle tissues were automatically re-
gistered using our newly developed software for SC segmentation,
called Schlemm I. This version provides the automatic registration and
segmentation based on three variables: (i) computation of the visual
and statistical cues of temporal mean, (ii) successive frame differences
and the speckle variance from the data, followed by (iii) successive
gray-level morphological operations to extract the vessel regions re-
liably from the rest (Huang et al., 2009). Hence, the outcome of
Schlemm I contains segmented SC along with several other vessels.
Note that this stage of segmentation is important for analysis of ves-
sels in general. With the options provided in the second version of the
software, called Schlemm II, SC is manually separated from the other
vessels. Manual separation is required since the visual and statistical
cues cannot properly differentiate SC from other vessels. SC is easily
differentiated from other vessels due to its size and location. In terms
of manual control, Schlemm II has options for freehand drawing,
erasing and choosing appropriate regions to incorporate in the ﬁnal
segmentation. The important feature for Schlemm II is that the re-
gistered B-scans are periodically displayed as live images alongside
the averaged image during segmentation, which makes comparison
and segmentation much easier. The segmentation results in this study
are based on the outputs from this stage. The inter-observer repeat-
ability is also tested based on the outputs of this stage, since the au-
tomatic segmentation provides robust output to the point of separ-
ating the important vessel structures from the background, but not a
complete segmentation of the SC. Hence, the robustness of the ﬁnal
segmentation is assured via a repeatability test.
After the second stage of the segmentation, the background re-
gions are segmented automatically from the foreground since the
foreground is already deﬁned in Schlemm II, containing the required
vessel structure. Also, the outcome of Schlemm II containing all ves-utﬂow tissue responses to netarsudil in living mouse eyes. Eur J
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iance regions generated by blood cells or other reﬂectors in vessels
(Hendargo et al., 2013; Huang et al., 2009; Li et al., 2014a; Mar-
iampillai et al., 2008; Poole et al., 2014) were automatically segmented
by the third version of the software, Schlemm III, that includes several
statistical analysis tests to measure the shape, size, location and var-
iation of speckling in different vessels as well as the SC.
2.8. Reproducibility
To validate application of our new software, we performed two
studies to assess interobserver and intraobserver reproducibility. The
segmentation of SC was independently performed by two individuals;
one reviewed the images without knowing the treatments to assess
the interobserver reproducibility. The other observer repeated the
measurement one to two months after the ﬁrst examination to de-
termine intraobserver reproducibility.
2.9. Histology
C57 and CD1 mice were each given one 10 ml drop of 0.04%
netarsudil in one eye and a 10 ml drop of placebo in the con-
tralateral eye. Fifty minutes after treatment, both eyes were col-
lected, immersed into 4% paraformaldehyde, and kept at 4 °C
overnight. The eyes were then bisected and the posterior segments
and lenses were removed. The anterior segments were cut into
four quadrants and each quadrant was embedded into Epon
(Electron Microscopy Sciences, ON, Canada). The blocks were cut
into 0.5 mm semi-thin sections and stained with 1% methylene
Blue. The images were captured digitally using light microscopy.3. Results
3.1. Topical netarsudil decreases intraocular pressure in mice
To test the effects of netarsudil on IOP in young mice (2–4 months
old), 10 ml of 0.04% netarsudil and placebo eye drops were given to-
pically once daily to a single eye of two different cohorts of mice. IOP
was measured before eye drops were given and for ﬁve consecutive
days of treatment. As shown in Fig. 1A, netarsudil signiﬁcantlyFig. 1. Netarsudil lowered intraocular pressure (IOP) in both pigmented and nonpigmented
gender-matched groups (5 mice/group, 4 groups total). For each strain of mice, one group
placebo (CF324–01) eye drop. All eye drops were applied to right eyes. IOP was measur
ΔIOP compared between netarsudil and placebo-treated group analyzed by Mann Whit
Please cite this article as: Li, G., et al., Visualization of conventional o
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(range 3.7–6.8 mmHg), with an average IOP-lowering of 5.2 mmHg
over the course of the experiment compared to the contralateral un-
treated eye. Interestingly, netarsudil was not as effective in albino, CD1
mice, signiﬁcantly lowering IOP an average of 2.2 mmHg (ranging 1.3–
2.8 mmHg) (Fig. 1B). IOP in eyes receiving placebo eye drops increased
on average by 1.4 mmHg compared to their contralateral untreated
eyes in both strains of mice (1.3770.21 mmHg in C57 and
1.3870.23 mmHg in CD1).
3.2. Netarsudil improves IOP recovery and outﬂow facility in mouse
eyes
We used two methods, a pressure-decay technique in living
eyes and an automated perfusion assay of enucleated mouse eyes,
to examine whether reduction of IOP by netarsudil was a result of
increased outﬂow facility. Recovery from provocative IOP elevation
over time was evaluated simultaneously in paired eyes of living
mice, with one eye perfused with the active metabolite of ne-
tarsudil and the other with vehicle. As shown in Fig. 2A, pressure
dropped faster in the netarsudil-M1 perfused eyes compared to
vehicle control. After ﬁtting the curves to Eq. (1) described in
Methods, we found that overall netarsudil-M1 treatment resulted
in a signiﬁcant 22% decrease in pss and 25.3% increase in α. The
decrease in pss can be caused by a decrease in episleral venous
pressure, aqueous humor secretion, an increase in outﬂow facility,
or the combination of all three factors. While netarsudil has
known effects on all three parameters, its primary mechanism of
action involves effects on outﬂow facility, which is likely a domi-
nant factor in determining α.
We next tested netarsudil effects on outﬂow facility more speci-
ﬁcally in a controlled experimental environment, where conventional
outﬂow function was isolated from other physiological parameters
that affect IOP such as aqueous humor inﬂow, uveoscleral outﬂow and
episcleral venous pressure. Using an iPerfusion system (Sherwood
et al., 2016), we subjected enucleated mouse eyes to 9 sequential
pressure steps (4.5–21mmHg) and measured ﬂow. A sample ﬂow-
pressure plot for a C57mouse is given in Fig. 3A, showing a higher rate
of outﬂow for a given pressure in the netarsudil-M1 treated eye.
Whilst accounting for measurement uncertainty, we observed that
treatment with netarsudil-M1 yielded a proportional increase ofmice. Ten week-old C57 and 6–14 week-old CD1 mice were divided into 2 age and
was given 10 ml of 0.04% netarsudil topically, and another group received 10 ml of a
ed in both eyes before eye drops were given. The data represent mean 7 S.E.M. of
ney U test. *, Po0.05;**, Po0.01.
utﬂow tissue responses to netarsudil in living mouse eyes. Eur J
Fig. 2. Netarsudil enhanced IOP recovery in living mouse eyes. Vehicle (0.001% DMSO) or 100 nM netarsudil-M1 was preloaded into one of two perfusion needles and inserted
intracamerally into contralateral eyes of living mice. Both eyes were simultaneously exposed to intraocular pressure (IOP) of 15 mmHg, allowing drug/vehicle to enter eyes
for 30 min IOP was artiﬁcially raised to 40 mmHg in both eyes and held for 5 min using a ﬂuid reservoir. Connection to the ﬂuid reservoir was closed, but remained open to
pressure transducers, which monitored IOP in both eyes over time. Panel A. Representative IOP decay curves in paired eyes exposed to vehicle (DMSO) or netarsudil-M1.
Panel B. Relative changes in α (a constant characterizing the rate of pressure decay). The data represent mean 7 S.E.M., N¼8,**, Po0.01 by student t-test.
Fig. 3. Netarsudil increased outﬂow facility in perfused mouse eyes ex vivo. Outﬂow facility measurement was conducted in paired enucleated eyes using an iPerfusion system.
The drug (netarsudil) and vehicle (0.001% DMSO) were preloaded in microneedles and perfused for 45–60 min before exposing eyes to 9 sequential pressure steps. Panel A.
Representative experiment showing ﬂow rate (Q) vs pressure (P) that was used to calculate outﬂow facility in a single pair of eyes. Panel B. Cello plot (Sherwood et al., 2016)
shows percentage change in facility for each pair of eyes in response to treatment with netarsudil. Dark blue error bars indicate conﬁdence interval from the ﬁtting of the
model to the ﬂow-pressure data and lighter error bars include additional uncertainty arising from differences between contralateral eyes of C57BL/6 mice (Sherwood et al.,
2016). Shaded region shows estimated lognormal distribution of percentage change in facility. Outer white lines show 2 standard deviations and central lines shows the
average increase. Dark central band shows the 95% conﬁdence interval on the mean increase. N¼8, P¼0.006 by a paired weighted t-test. Panel C. Cello plot shows percentage
change in facility for each pair of eyes in response to treatment with netarsudil for CD1 mice. Lighter error bars assume that the additional uncertainty arising from
differences between contralateral eyes in CD1 mice is similar to that of C57 mice. N¼6, P¼0.025.
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[19, 104%], N¼8, P¼0.006) for C57 mice and 91% (95% conﬁdence
interval [12, 225%], N¼6, P¼0.025) for CD1 mice (Fig. 3C). The range
of treatment effect at two standard deviations was [1,146%] for C57
mice and [35, 223]% for CD1 mice.
3.3. Netarsudil increases ﬂuorescent tracer deposition in outﬂow
tissues
To test whether netarsudil effects on outﬂow in living mouse eyes
includes modiﬁcations in TM/SC ﬂow patterns, ﬂuorescent tracer was
perfused simultaneously under constant ﬂow conditions into paired
eyes in the presence or absence of netarsudil-M1. As observedPlease cite this article as: Li, G., et al., Visualization of conventional o
Pharmacol (2016), http://dx.doi.org/10.1016/j.ejphar.2016.04.002ipreviously (Swaminathan et al., 2013; Zhang et al., 2009), green
ﬂuorescent beads in control eyes deposited in outﬂow tissues in a
segmental pattern in both strains of mice, with high and low ﬂow
regions marked by high and low ﬂuorescence intensity, respectively
(Fig. 4A). In netarsudil-M1 perfused eyes, the ﬂuorescence intensities
were clearly increased in both high ﬂow and low ﬂow regions.
Quantitative measurements of the ﬂuorescence intensities, showed a
signiﬁcant increase in ﬂuorescence by 2.2-fold in C57 and 1.5-fold in
CD1 mouse eyes perfused with netarsudil-M1 compared to vehicle
control eyes (Fig. 4B). In order to examine whether increase of ﬂuor-
escence intensities correspond to the increase of tracer deposition of
outﬂow tissues, the width and areas of the ﬂuorescence in TM/SC
were also quantiﬁed as shown in Fig. 4B. Signiﬁcant increase of bothutﬂow tissue responses to netarsudil in living mouse eyes. Eur J
Fig. 4. Enhanced tracer deposition in outﬂow tissues of living mice subjected to netarsudil treatment. Fluorescent microbeads were loaded into microneedles in the presence or
absence of netarsudil-M1 anterior chambers were cannulated and paired eyes simultaneously perfused at a constant ﬂow rate of 0.167 ml/min. Perfusion was stopped after
one hour and the mice were maintained for another hour before being euthanized. Shown are ﬂat mounted anterior segments of C57 and CD1 mouse eyes that were
visualized using epiﬂuorescence microscopy (panel A). Summary of comparisons between netarsudil-M1-treated (NT) and vehicle (0.001% DMSO)-treated groups are shown
in panel B. Fluorescence intensity, the width and area of ﬂuorescence in conventional outﬂow region were automatically quantiﬁed. Data represent mean 7 S.E.M, N¼5 for
both strains of mice. *, Po0.05,**, Po0.01 compared to their contralateral vehicle treated eyes by student t-test. Panels C and D show representative ﬂuorescence intensity
and width maps of conventional outﬂow regions from four quadrants of paired eyes. The variation of mean intensity (of all pixels with identical angles to the center) (panels
C) and the variation of width (panels D) are shownwith the variation of angle from the center of the circular TM/SC regions (from 180 to 180 degrees). The 0 (180) degree is
represented by the positive X-axis.
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mouse TM/SC treated with netarsudil-M1. In CD1 mice, both width
and area were also slightly increased (1.22-and 1.27-fold), but did not
reach statistical signiﬁcance. Representative ﬂuorescence intensity and
width maps for four quadrants of paired eyes are shown in Fig. 4C and
D, respectively displaying quantitative spatial differences between
placebo and netarsudil-M1 treatments.
3.4. Dynamic changes in conventional outﬂow tissues of mouse eyes
treated with netarsudil visualized by OCT
In order to visualize behavior of conventional outﬂow tissues
treated with netarsudil, we used our custom-build OCT imaging sys-
tem for live mice. Iridocorneal angle tissues were imaged immediately
before, and 30–60min after topical netarsudil application. A re-
presentative series of OCT images of treated and untreated mouse
eyes are shown in Fig. 5A, displaying averaged images of 200 B-scan
frames with segmentation of SC lumen using Schlemm II software.
Alongside the segmented images are speckle variance OCT images
showing location of moving reﬂectors in iridocorneal vessels. DataPlease cite this article as: Li, G., et al., Visualization of conventional o
Pharmacol (2016), http://dx.doi.org/10.1016/j.ejphar.2016.04.002iillustrate that the SC cross sectional areawas signiﬁcantly increased by
48.2% after topical netarsudil treatment (P¼0.00005) compared to
11.5% decrease of the SC area after placebo treatment (P¼0.33, panel
B). Coincident with changes in SC lumen area, we also found that
netarsudil expanded the opening to the TM as shown in Fig. 5A (red
arrow). This OCT ﬁnding was conﬁrmed in a subsequent histological
study (supplementary Fig. 1), where both C57 and CD1 mice were
treated with topical netarsudil or placebo and eyes were processed
and analyzed. Consistent with the observation in living animals, TM
area was clearly expanded by netarsudil treatment in both strains of
mice. While area of scleral vessels did not change with treatment, we
did observe that their speckle variance intensity increased by 61.6%
(p¼0.03, Fig. 5 panel C). These changes were comparable to that of SC,
whose speckle variance increased by 34.2% after netarsudil treatment.
We found there was no effect of netarsudil on pupil diameter in OCT
images (data not shown).
We next examined the effects of netarsudil on outﬂow structures
in the presence of increasing IOPs. IOP was controlled by a single
needle inserted into the mouse anterior chamber in iridotomized eyes.
Similar to naive eyes, when IOP was held at near physiological IOPutﬂow tissue responses to netarsudil in living mouse eyes. Eur J
Fig. 5. Netarsudil-induced changes in conventional outﬂow tissue morphology of living mice visualized by optical coherence tomography (OCT). Panels A shows re-
presentative averaged OCT images from 200 B-scans of iridocorneal angles (identical positions) before and 45 min after topical netarsudil or placebo treatment of living C57
mice (IR: iris; black arrows point to TM tissue). Overlayed atop averaged images are segmentations (SEG, blue) of SC using Schlemm II software. Arrow in red, shows
expanded TM after netarsudil treatment. The speckle variance images (SPV) of same eyes are shown alongside averaged images. Arrows in white point out scleral vessels
conducting aqueous humor outﬂow and asterisks indicate SC. Panels B and C show quantitative results summarizing effect of treatments on area and speckle variance
intensity of SC and scleral vessels conducting aqueous humor outﬂow using Schlemm III software. The data represent mean 7 S. E. M.. N¼5 for each treatment. *Po0.05
(student t-test).
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by 32% and 29% in C57 and CD1 mice, respectively (Fig. 6). We ob-
served that SC lumen dimensions were decreased at elevated pres-
sures, which is consistent with our previous observations using
manual segmentation (Li et al., 2014a). However, after topical ne-
tarsudil treatment SC was signiﬁcantly less compressed at all IOPs
tested. Thus, netarsudil functions to prevent SC collapse as IOP in-
creases. In contrast, placebo drops had no effect on the SC area,
whether IOP was elevated or not (Fig. 6B and C).
3.5. Effects of netarsudil on scleral vessel cross-sectional area, ﬂow
patterns and speckle variance intensity
We next visualized and analyzed effects of netarsudil on scleral
vessels that conduct aqueous humor when IOP was held constant at
10 mmHg. We found that netarsudil changed the ﬂow patterns
and speckling intensity in scleral vessels of living C57 and CD1 mice
as shown in Fig. 7A. Quantiﬁcation of total speckle variance inPlease cite this article as: Li, G., et al., Visualization of conventional o
Pharmacol (2016), http://dx.doi.org/10.1016/j.ejphar.2016.04.002icross-sections (indicating vessels carrying aqueous humor) and in-
tensities are shown in Fig. 7B and C. The total cross-sectional area of
scleral vessels conducting aqueous humor outﬂow increased from
433.47170.1 mm2 before netarsudil treatment to 734.97243 mm2
after treatment in C57 mice (P¼0.037). Similarly, vessel area increased
from 531.37147.2 mm2 to 965.97233.2 mm2 in presence of netarsudil
in CD1 mice (P¼0.0009). In vehicle-treated groups, the areas changed
from 377.47122.4 mm2 before placebo to 446.87119.3 mm2 after
placebo in C57 mice (P¼0.46) and from 559.17184.9 mm2 to
474.47186.5 mm2 after placebo in CD1 mice (P¼0.79). The relative
speckle variance intensity within single vessels also increased after
netarsudil treatment, suggesting an increase in ﬂuid ﬂow. In C57 and
CDI mice, speckle variance intensity increased by 72.9% (P¼0.023) and
27% (P¼0.43), respectively. There was no difference after placebo
treatment in either C57 mice or CD1 mice (Fig. 7B and C). These data
are similar to experiments conducted in naive eyes (not cannulated)
whereby speckle intensity increased, but interestingly cross-sectional
area remained the same (Fig. 5C).utﬂow tissue responses to netarsudil in living mouse eyes. Eur J
Fig. 6. Netarsudil increased cross-sectional area of Schlemm’s canal (SC) lumen in living mice with elevated intraocular pressure (IOP) visualized by optical coherence
tomography (OCT). Panel A shows representative averaged images from 200 B-scans of iridocorneal angles (identical positions) of a live C57 mouse before and 40 min after
netarsudil treatment, with IOP held at 10 mmHg. Semi-automatic segmentation (SEG) of SC is shown overlayed in blue. Bottom panels show OCT speckle variance (SPV)
images. (IR ¼ iris). Panels B and C show results of quantitative SC segmentation from OCT images analyzed using Schlemm II software. C57 and CD1 mouse eyes were imaged
at the same location by OCT with a glass needle inserted into anterior chamber to control intraocular pressure sequentially at 10, 15, and 30 mmHg before and 30–60 min
after treatment (topical netarsudil or placebo eye drops). The data show SC area (7 S. D.) relative to the area of SC measured just prior to treatment at the starting IOP of
10 mmHg. Eleven mice were examined in this set of experiments. *Po0.05;**Po0.01 (Mann Whitney U test).
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The results of this study provide further evidence that mice are
a useful model to study drugs that target conventional outﬂow
function. Netarsudil has previously been shown to lower IOP in
humans (Bacharach et al., 2015; Lewis et al., 2015; Wang et al.,
2015) and to increase outﬂow facility in non-human primates
(Wang et al., 2015). We demonstrated that netarsudil also effec-
tively lowers IOP and increases outﬂow facility in both albino and
pigmented mice. To better understand its mechanism of action, we
probed for real time drug effects on conventional outﬂow dy-
namics using OCT of living mice. We observed that netarsudil
treatment expanded the opening to conventional outﬂow tissues,Please cite this article as: Li, G., et al., Visualization of conventional o
Pharmacol (2016), http://dx.doi.org/10.1016/j.ejphar.2016.04.002iincreased the cross-sectional area of SC, and prevented its collapse
at elevated IOPs. Netarsudil also increased speckle variance in-
tensity in both SC and scleral vessels that conduct aqueous humor
outﬂow. These changes were reproducibly quantiﬁed using our
newly developed segmentation software. Taken together, these
results demonstrate that netarsudil robustly lowers IOP by af-
fecting both proximal and distal portions of the conventional
outﬂow tract.
Contractile tone of conventional outﬂow tissue determines outﬂow
facility (Dismuke et al., 2014; Zhou et al., 2012). Studies have shown
that TM cells possess smooth muscle-like properties, and that drugs
relaxing TM cells increase outﬂow while drugs contracting TM cells
decrease outﬂow (McKee et al., 2011; Rao et al., 2001; Rosenthal et al.,utﬂow tissue responses to netarsudil in living mouse eyes. Eur J
Fig. 7. Netarsudil-induced changes in ﬂow area and intensity in scleral vessels visualized on OCT speckle variance images. Panel A shows representative speckle variance images
of C57 and CD1 mouse outﬂow tissues before and after netarsudil or placebo eye drops. Arrows show scleral vessels before and 30–60 min after netarsudil treatment. Panels
B and C show a summary of quantitative segmentation data expressed as relative changes in scleral vessel cross-sectional area and intensity after netarsudil or placebo
treatment in C57 pigmented versus CD1 non-pigmented mice. Speckle variance images were visualized by Schlemm II software, and the areas of the intrascleral plexi near SC
were selected for analysis. Speckle variance intensities in those areas were analyzed using Schlemm III software. The data represent mean 7 S.E.M,, N¼4–5 from each group
and each strain of mice,*, Po0.05 (Student's t-test).
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known to decrease actomyosin-based cellular contraction by reducing
the number of actin stress ﬁbers and focal adhesions in conventional
outﬂow cells (Nakajima et al., 2005; Rao et al., 2001). These changes in
the actomyosin cytoskeleton and cell adhesive properties result in
separation of the outermost cribiform plate from the inner wall of SC
(Gong and Yang, 2014; Yang et al., 2013). This separation increases
access of aqueous humor to the inner wall and theoretically eliminates
resistance-generation due to “funneling” (Overby et al., 2009). Con-
sistent with these previous studies (Yang et al., 2013), we visualized
expansion of the TM using two different methods. Importantly, we
demonstrate for the ﬁrst time that rho-kinase-induced changes in TM
shape can be resolved in living mice using OCT. Coincident with these
changes, we observed that the cross-sectional area of SC increased 30–
60min (time period the experiments were conducted) after netarsudil
treatment in both naïve and IOP-controlled eyes. Theoretically, re-
laxation of TM and inner wall separation should reduce SC lumen
area, not increase it. However, since netarsudil is also known to lower
episcleral venous pressure (28), reduction of downstream pressure in
the context of reduction of resistance at SC/JCT prevents SC com-
pression and promotes ﬂow into and ﬁlling of SC lumen.
Fluorescent microbead tracer was used in the current study to
determine netarsudil's effects on the patterns of aqueous humor
outﬂow in the conventional tract. Netarsudil increased tracer de-
position width and area, plus increased ﬂuorescent intensity, in-
dicating that more ﬂuid passed through those regions to depositPlease cite this article as: Li, G., et al., Visualization of conventional o
Pharmacol (2016), http://dx.doi.org/10.1016/j.ejphar.2016.04.002ibeads in the TM. It has been reported that reduced deposition of
ﬂuorescent tracer in outﬂow tissues correlates with elevated IOP
and increased outﬂow resistance in both mouse and monkey eyes
(Swaminathan et al., 2013; Zhang et al., 2009). Y27632, a relatively
weak, non-selective rho kinase inhibitor increases tracer deposi-
tion in outﬂow tissues of enucleated bovine, monkey and human
eyes ex vivo (Gong and Yang, 2014; Lu et al., 2008; Lu et al., 2011).
We observed a similar pattern of increased bead decoration in
mouse outﬂow tissues after netarsudil treatment in both low and
high ﬂow regions, which corresponded to increased outﬂow fa-
cility and lower IOP.
Impairment in outﬂow facility is responsible for ocular hy-
pertension and large diurnal IOP ﬂuctuations in glaucomatous eyes
(Brubaker, 2003). Treatments, such as rho kinase inhibitors, that
act by enhancing outﬂow facility are beneﬁcial because they cor-
rect the physiological deﬁcit in aqueous humor dynamics. Ad-
ditionally, they may ﬂatten diurnal IOP curves plus help alleviate
the pressure spikes that occur with everyday events, such as
choroidal expansion upon awakening from sleep (Brown et al.,
1988; Zeimer et al., 1990). In the present study we modeled in
living mice the IOP spike that occurs every morning upon awa-
kening. As theorized (Brubaker, 2001), we show experimentally for
the ﬁrst time that a conventional outﬂow drug speeds IOP re-
covery by 25%. While enhancement of outﬂow facility by ne-
tarsudil is likely the primary effect on IOP decay, other parameters
such as ocular compliance, inﬂow, episcleral venous pressure andutﬂow tissue responses to netarsudil in living mouse eyes. Eur J
Video 2A. Comparison of outﬂow tissue behavior of living mouse eyes before and
after Netarsudil treatment using OCT OCT videos show representative behavior of
iridocorneal angle tissues from linear 200 B-scans (identical positions) of a live C57
mouse before (Video S2a) with intraocular pressure held at 10 mmHg. Video S2a
shows speckling in SC, collector channel and scleral vessels. A video clip is available
online.Supplementary material related to this article can be found online at http://
dx.doi.org/10.1016/j.ejphar.2016.04.002.
Video 2B. A Comparison of outﬂow tissue behavior of living mouse eyes before and
after Netarsudil treatment using OCT OCT videos show representative behavior of
iridocorneal angle tissues from linear 200 B-scans (identical positions) of a live C57
mouse 40 min after topical 0.04% netarsudil treatment (Video S2b) with intraocular
pressure held at 10 mmHg. In Video S2b, the speckling area of SC lumen enlarges,
and collector channels widen after netarsudil treatment.Supplementary material
related to this article can be found online at http://dx.doi.org/10.1016/j.ejphar.2016.
04.002.
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stration shows that drugs that primarily target outﬂow facility
reduce the integrated IOP insult that are imparted to susceptible
retinal ganglion cell axons at the optic nerve head.
Besides its primary mechanism as a rho kinase inhibitor, ne-
tarsudil also functions as an inhibitor of norepinephrine trans-
porter (NET) (Kiel and Kopczynski, 2015; Wang et al., 2015). NET
inhibition in the ciliary body is thought to increase norepinephrine
levels and thereby decrease aqueous humor secretion via activa-
tion of α2 adrenergic receptors. As a third mechanism of action,
netarsudil has been shown to decrease episcleral venous pressure
in rabbits (Kiel and Kopczynski, 2015), which may be related to the
rho kinase inhibitors’ ability to promote vasodilation (Somlyo,
1997). Consistent with this possibility, we detected by OCT ne-
tarsudil-mediated increase in cross-sectional area of scleral vessels
and SC. Studies have shown that elevated rho kinase pathway
activity is associated with a variety of vascular diseases (Noma
et al., 2006) and may play a pivotal role in cardiovascular diseases
such as vasospastic angina, ischemic stroke, and heart failure. It is
unclear whether elevated rho kinase activity may underlie ocular
hypertension in glaucoma.
The development of software that can quantitatively measure the
cross sectional area of SC and scleral vessels from OCT images, plus
detect the ﬂow pattern of perfused scleral vessels and changes of
speckle variance intensities is another major achievement in this
study. In two previous reports we quantiﬁed SC areas from OCT
images using manual segmentation methods (Li et al., 2014a, 2014b).
Not surprisingly, this is a laborious and subjective task, requiring
extensive experience working with OCT images of mouse outﬂow
tracts, multiple readers and masking of samples. In order to provide
a more objective and rapid method to evaluate ocular vessels, we
have designed novel segmentation software for use in the anterior
segment of the eye. This new software sequentially processes ima-
ges, reproducibly and efﬁciently segmenting SC based upon three
factors: stable pixels of the outer wall of SC, speckle variance in SC
delimiting its inner wall, plus successive B-scan differences to en-
hance contrast of the subtle ﬂow patterns. Importantly, we found
that the interobserver-reproducibility of the software was 91.7%
77.43% and intraobserver-reproducibility was 99.2%70.48%. This
represents a signiﬁcant improvement in reproducibility compared to
the ImageJ software we used in our previous study (intraobserver-
reproducibility ¼86.2%711.5%) (Li et al., 2014a).
In the current study, we also found that netarsudil increased
speckle variance areas and intensities inside of scleral vessels that
likely conduct aqueous humor. Speckle variance is a phenomenon
caused by moving OCT reﬂectors, such as lipid and blood cells.
Changes in speckle on OCT images in regions of ﬂowing blood have
been described earlier (Barton and Stromski, 2005; Barton et al.,
2001). Whether the increase of speckle variance areas and intensities
by netarsudil correlates with increased ﬂow velocity in scleral vessels
is unknown and needs to be further investigated. Also important is
determining the exact identity of the reﬂectors in the conventional
outﬂow tract.
A limitation of the present study is that we only monitored the
acute effects of netarsudil by OCT in young mice. Our next goal is to
chronically treat mice (young and aged) with netarsudil and examine
the effect of long-term treatment on outﬂow facility, outﬂow tissue
morphology and behavior via OCT. A second limitation is that we only
imaged one OCT volume of each mouse eye. We are developing
methods to image larger regions (i.e. imaging the entire interval be-
tween two adjacent collector channels), with the ultimate goal of
imaging outﬂow structures for 360 degrees following different treat-
ments or manipulations. These advances will provide much needed
information about conventional outﬂow dynamics, and may ulti-
mately assist physicians in medical decision-making regarding glau-
coma care.Please cite this article as: Li, G., et al., Visualization of conventional o
Pharmacol (2016), http://dx.doi.org/10.1016/j.ejphar.2016.04.002i5. Conclusions
The present study documents the dynamic effects of a novel
glaucoma drug, netarsudil, currently in phase III clinical trials. We
examined IOP, outﬂow function and conventional outﬂow morphol-
ogy in living mice. Results show that netarsudil impacted both prox-
imal and distal portions of the conventional outﬂow tract to reduce
outﬂow resistance and lower IOP. This is the ﬁrst report showing real-
time, non-invasive drug effects on conventional outﬂow tissues in
living eyes, paving the way for development of a clinic-friendly OCT
platform for glaucoma.Acknowledgments
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